- Trials with a EudraCT protocol (330)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
330 result(s) found for: Endometrial.
Displaying page 9 of 17.
EudraCT Number: 2017-004664-36 | Sponsor Protocol Number: EVE116-CT03-2017 | Start Date*: 2018-06-19 |
Sponsor Name:Evestra GmbH | ||
Full Title: Characterization of ovulation inhibition of a new vaginal delivery system containing trimegestone - an open-label, single-centre study in healthy females of childbearing potential | ||
Medical condition: Investigation of ovulation inhibition for indication of contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000693-30 | Sponsor Protocol Number: 56UCS2017 | Start Date*: 2019-11-25 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. | |||||||||||||
Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001588-19 | Sponsor Protocol Number: MVT-601-3101 | Start Date*: 2017-11-01 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) HU (Completed) BE (Completed) PL (Completed) BG (Completed) PT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002897-27 | Sponsor Protocol Number: 18E-Prg06 | Start Date*: 2018-12-21 | |||||||||||
Sponsor Name:IBSA, Institut Biochimique, S.A. | |||||||||||||
Full Title: A proof of concept, randomized, controlled clinical trial to assess the efficacy of subcutaneous progesterone (Prolutex) versus vaginal proges-terone (Progeffik) for endometrial preparation in wome... | |||||||||||||
Medical condition: Infertility. Assisted Reproductive Tecniques. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000189-31 | Sponsor Protocol Number: PRI04/2016 | Start Date*: 2017-05-12 |
Sponsor Name:Pannon Reprodukciós Intézet B.1.2 | ||
Full Title: Optimization and Safety Testing of Hormone Normalization Therapy in Advanced Maternal Age Infertile Women | ||
Medical condition: The therapy is intended to treat infertility that is caused by declining egg quality that occurs with advanced maternal age. The purpose of this pilot trial is to optimize the therapeutic protocol.... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000572-41 | Sponsor Protocol Number: LUC19-002 | Start Date*: 2019-04-29 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced « cold » solid tumors | ||
Medical condition: Indication of treatment with anti-PD1 antibodies such as • Melanoma non BRAF mutated in first line of treatment • Melanoma BRAF mutated in first or second line of treatment • Lung cancer (NSCLC) in... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001809-40 | Sponsor Protocol Number: MER001 | Start Date*: 2015-09-10 | |||||||||||
Sponsor Name:IDIPAZ | |||||||||||||
Full Title: Scheduling of GnRH antagonist FIV-ICSI cycles with estrogen or contraceptive oral pills in previous luteal phase. Comparison of results against no treatment. | |||||||||||||
Medical condition: Sterility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004545-91 | Sponsor Protocol Number: 59874 | Start Date*: 2017-04-13 |
Sponsor Name:VU University Medical Center, department of reproductive Medicine | ||
Full Title: Continuous use of Oral contraceptives as an alternative for long term Pituitary down-regulation with GnRH agonist prior to IVF/ICSI in Endometriosis patients: a randomised controlled trial (COPIE t... | ||
Medical condition: The research population consists of women with surgically confirmed endometriosis ASRM stage III or IV or endometrioma on transvaginal ultrasound or MRI, scheduled for an IVF/ICSI treatment. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005683-41 | Sponsor Protocol Number: RIOTB2015 | Start Date*: 2016-03-16 | |||||||||||||||||||||
Sponsor Name:Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital | |||||||||||||||||||||||
Full Title: REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES ... | |||||||||||||||||||||||
Medical condition: Infertility | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012300-69 | Sponsor Protocol Number: Number 1 | Start Date*: 2010-03-26 |
Sponsor Name:Meander Medisch Centrum | ||
Full Title: Does vitamin D deficiency contribute to fatigue in patients in remission after treatment of gynaecological malignancy? | ||
Medical condition: Vitamin D deficiency in patients in complete remission after successful treatment of a gynaecological malignancy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000500-13 | Sponsor Protocol Number: 8821 | Start Date*: 2005-08-15 |
Sponsor Name:University of Oxford- Research Services | ||
Full Title: Metformin treatment before IVF in women with ultrasound evidence of polycystic ovaries; a prospective, randomised, double blind, placebo controlled study | ||
Medical condition: Infertile women undergoing IVF with sonographic evidence of polycystic ovaries but without any clinical manifestations of polycystic ovarian syndrome. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000811-24 | Sponsor Protocol Number: 308260 | Start Date*: 2004-11-19 | |||||||||||
Sponsor Name:Schering AG | |||||||||||||
Full Title: Multicenter, double-blind, randomized, pleacebo-controlled study to evaluate the oral low-dose estradiol preparations SH T 04170 E (100 µg estradiol) and SH T 04170 F (190 µg estradiol) in postmeno... | |||||||||||||
Medical condition: postmenopausal women with high risk for osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003602-16 | Sponsor Protocol Number: PM1183-A-014-15 | Start Date*: 2022-02-24 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003002-10 | Sponsor Protocol Number: GINECO-EN101 | Start Date*: 2007-10-09 | |||||||||||
Sponsor Name:ARCAGY-GINECO | |||||||||||||
Full Title: A multicentre phase II study, estimating the efficiency and the tolerance of RAD001 (Everolimus) , in patients with endometrial metastatic cancer resistant to a first line of chemotherapy | |||||||||||||
Medical condition: Endometrial metastatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004267-40 | Sponsor Protocol Number: MIT-Es0001-C202 | Start Date*: 2017-01-16 | |||||||||||
Sponsor Name:Estetra SPRL | |||||||||||||
Full Title: A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRE... | |||||||||||||
Medical condition: Hormonal contraception in woman seeking contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001182-21 | Sponsor Protocol Number: APC-01-2021 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:University Hospital Puerta de Hierro Majadahonda, Madrid, Spain | |||||||||||||
Full Title: RANDOMIZED, UNICENTRIC, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY OF PARACERVICAL ANESTHESIA FOR PAIN CONTROL DURING AN OFFICE HYSTEROSCOPY | |||||||||||||
Medical condition: Need to do an office Hysteroscopy for any reason | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004043-21 | Sponsor Protocol Number: 16-OBE2109-016 | Start Date*: 2018-10-17 |
Sponsor Name:ObsEva SA | ||
Full Title: An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis. | ||
Medical condition: Rectovaginal endometriosis | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-002350-22 | Sponsor Protocol Number: LR-201 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28... | |||||||||||||
Medical condition: Women´s healthcare (Contraception, inhibition of ovulation) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004112-10 | Sponsor Protocol Number: PROTECTA | Start Date*: 2020-12-16 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Randomized controlled trial comparing micronized progesterone (Amelgen ®) 400 mg BID versus 400 mg TID for luteal support in artificial vitrified/warmed single blastocyst transfer cycles with low p... | ||
Medical condition: Patients who undergo artificial vitrified/warmed single blastocyst transfer cycles with low progesterone (defined as <10mcg/l) on day of embryo transfer. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
